MorphoSys AG partnered its anti-CD38 mAb MOR202 earlier than planned, as an upwelling of interest in the cancer target prompted Celgene Corp. to offer terms the German biotech couldn't refuse.

CD38 is a multifunctional ectoenzyme involved in cell adhesion that is overexpressed in hematological tumors, where it is believed to play an important role in tumor cell migration and metastasis.